This book offers a progress report on efforts to meet the challenges faced by ovarian cancer patients and their doctors. It provides a current perspective on therapeutic developments as a partnership between laboratory-based and clinical-based researchers.
1Existing treatment for ovarian cancer: recent advances and description of unmet needsS BanerjeeM BookmanM Gore2Discovery of novel targetsJ FarleyM Birrer3Anti-angiogenesis update on its application in ovarian cancerJ HasanG Jayson4Targeting the PI3K/AKT pathwayE StronachA Cheraghchi-BashiM ChenH Gabra5Inhibition of the SRC oncogene; potential in ovarian cancerLY HanAK Sood6Tumour specific synthetic lethality; targeting BRCA gene dysfunctionTA YapSB KayeA AshworthA Tutt7Inhibition of cytokines and chemokines in ovarian cancerJ CowardF Balkwill8Potential for inhibition of membrane receptors (EGF, IGF, c-MET, and others)LP MartinJJ PerkinsR Schilder9An epigenetic approach to ovarian cancerR BrownN Chapman-RotheR Glasspool10Immunotherapy; update on its application in ovarian cancerS Ghaem-MaghamiM Gore11Ovarian cancer progenitor/stem cells; therapeutic potentialS MurphyA Berchuck12Potential for ?-folate receptor targeted treatment for ovarian cancerCHM NgA Jackman13New insights into tubulin bindersJ BrentonDespite rapid advances in understanding the biology of ovarian cancer, progress in treatment has been slow. But the prospects for improvement have never been better. A wide range of novel therapeutic targets now present themselves for clinical evaluation and initial results are certainly encouraging.In this text, all these areas are covered by experts in the field. Each chapter provides up-to-date coverage of clinical information, prefaced by a description of the rational basis for the selection of each target area and consideration of biomarkers that can be used to aid clinical evaluation.The four editors work together within the Ovarian Cancer Action collaboratlc!